Literature DB >> 1930880

Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats.

J Maj1, Z Rogóz, G Skuza.   

Abstract

MK-801, a non-competitive NMDA receptor antagonist, induced the locomotor hyperactivity in rats. Imipramine (IMI), amitriptyline (AMI), citalopram (CIT) given acutely increased the MK-801-induced locomotor hyperactivity. Mianserin (MIA) showed a similar but weaker effect. Haloperidol completely blocked the hyperactivity induced by the antidepressant drug (AD) + MK-801. Prazosin had an only weak antagonistic effect. Repeated treatment with AD increased the MK-801 locomotor hyperactivity to a greater extent than acute treatment. This effect was completely blocked by haloperidol and only partly by prazosin. The obtained results indicate that the dopamine system may be involved, at least in part, in the potentiating effect of the combined treatment with AD + MK-801.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1930880     DOI： 10.1007/bf01244943

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  31 in total

1.  Antidepressant drugs affect dopamine uptake.

Authors:  A E Halaris; K T Belendiuk; D X Freedman
Journal:  Biochem Pharmacol       Date:  1975-10-15       Impact factor: 5.858

2.  [3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes.

Authors:  E H Wong; A R Knight; G N Woodruff
Journal:  J Neurochem       Date:  1988-01       Impact factor: 5.372

3.  MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.

Authors:  M Morelli; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1990-07-17       Impact factor: 4.432

4.  Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc.

Authors:  I J Reynolds; R J Miller
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

5.  Dopaminergic stimulation enhances the utilization of noradrenaline in the central nervous system.

Authors:  J Maj; E Mogilnicka; V Klimek
Journal:  J Pharm Pharmacol       Date:  1977-09       Impact factor: 3.765

Review 6.  Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters.

Authors:  B Meldrum
Journal:  Clin Sci (Lond)       Date:  1985-02       Impact factor: 6.124

7.  Functional antagonists at the NMDA receptor complex exhibit antidepressant actions.

Authors:  R Trullas; P Skolnick
Journal:  Eur J Pharmacol       Date:  1990-08-21       Impact factor: 4.432

8.  Central dopaminergic transmission is selectively increased in the limbic system of rats chronically exposed to antidepressants.

Authors:  G M De Montis; P Devoto; G L Gessa; D Meloni; A Porcella; P Saba; G Serra; A Tagliamonte
Journal:  Eur J Pharmacol       Date:  1990-05-03       Impact factor: 4.432

9.  MK-801-induced stereotypy and its antagonism by neuroleptic drugs.

Authors:  P I Tiedtke; C Bischoff; W J Schmidt
Journal:  J Neural Transm Gen Sect       Date:  1990

10.  Chronic imipramine reduces [3H]SCH 23390 binding and DA-sensitive adenylate cyclase in the limbic system.

Authors:  G M De Montis; P Devoto; G L Gessa; D Meloni; A Porcella; P Saba; G Serra; A Tagliamonte
Journal:  Eur J Pharmacol       Date:  1989-08-22       Impact factor: 4.432
View more
  3 in total

Review 1.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

2.  The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist.

Authors:  J Maj; Z Rogóz; G Skuza; K Wedzony
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats.

Authors:  K Wedzony; K Gołembiowska; M Zazula
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.